Citations

Clear

7732 citation(s) found for "Ma, Daniel".

ECG-Gated Cardiac CT Angiography Using 64-MDCT for Detection of Patent Foramen Ovale
Williamson, Eric E. , Kirsch, Jacobo , Araoz, Philip A. , Edmister, Whitney B., Borgeson, Daniel D., Glockner, James F., Breen, Jerome F.

Mayo Clinic

American Journal of Roentgenology | March 20, 2008 | Volume: 190 | Issue: 4 | Pages: 929-933

10.2214/ajr.07.3140 | PMID 18356439 Get It

Human phenylethanolamineN-methyltransferase genetic polymorphisms and exercise-induced epinephrine release
Snyder, Eric M., Salavaggione, Oreste E., Moon, Irene, Batzler, Anthony , Yee, Vivien C., Schaid, Daniel J. , Johnson, Bruce D., Weinshilboum, Richard M. , Ji, Yuan , Fridley, Brooke L. , Joyner, Michael J. , Weinshilboum, Richard M.

Mayo Clinic

Physiological Genomics | March 19, 2008 | Volume: 33 | Issue: 3 | Pages: 323-332

10.1152/physiolgenomics.00248.2007 | PMID 18349382 Get It

Phenylethanolamine N-methyltransferase (PNMT) catalyzes the synthesis of epinephrine from norepinephrine. We previously identified and functionally characterized common sequence variation in the PNMT gene. In the present study, we set out to determine whether common PNMT genetic polymorphisms might be associated with individual variation in circulating epinephrine levels during exercise in 74 Caucasian American subjects. Circulating epinephrine levels were measured in each subject at baseline and during two different levels of exercise, ∼40% and ∼75% of peak workload. The PNMT gene was resequenced with DNA from each study subject. Eight novel PNMT polymorphisms were identified, including a C319T (Arg107Cys) nonsynonymous single nucleotide polymorphism (SNP) and I1G(280)A, a SNP located in the first intron of the gene. The I1G(280)A SNP was significantly associated with decreased exercise-induced circulating epinephrine levels and with a decreased epinephrine-to-norepinephrine ratio. The Cys107 recombinant allozyme displayed significantly lower levels of both PNMT activity and immunoreactive protein than the wild-type allozyme after transfection into COS-1 cells, but it did not appear to be associated with level of epinephrine in these subjects. Electrophoretic mobility shift and reporter gene assays performed with the I1G(280)A SNP indicated that this polymorphism could bind nuclear proteins and might modulate gene transcription. Our studies suggest that functionally significant variant sequence in the human PNMT gene might contribute to individual variation in levels of circulating epinephrine during exercise.
Comparative Bioavailability of Sulindac in Capsule and Tablet Formulations
Mandrekar, Sumithra J. , Carlson, Elsa C., Harmsen, William S. , McGovern, Renee M., Ames, Matthew M. , Boring, Daniel, Network, for the Cancer Prevention, Reid, Joel M. , Green, Erin M. , Szabó, Éva , Limburg, Paul J. , Network, for the Cancer Prevention

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | March 18, 2008 | Volume: 17 | Issue: 3 | Pages: 674-679

10.1158/1055-9965.epi-07-2510 | PMID 18349286 Get It

Abstract The cyclooxygenase (COX)-2 enzyme appears to be an important target for cancer chemoprevention. Given the recent emergence of potentially serious cardiovascular toxicity associated with selective COX-2 inhibitors, nonsteroidal antiinflammatory drugs (NSAIDs), which inhibit both COX-1 and COX-2, have received renewed attention as candidate chemoprevention agents. Sulindac has shown consistent chemopreventive potential in preclinical studies as well as in a limited number of clinical trials reported to date. For the current pharmacokinetic study, sulindac capsules were prepared to facilitate ample agent supplies for future intervention studies. Encapsulation of the parent compound (sulindac sulfoxide) can be readily accomplished, but the effects of alternate formulations on bioavailability have not been rigorously examined. In the present single-dose, two-period crossover trial, we conducted pharmacokinetic analyses of sulindac in capsule (test) versus tablet (reference) formulations. Overall, bioavailability appeared to be higher for the capsule compared with the tablet formulation based on test-to-reference pharmacokinetic variable ratios for the parent compound alone. However, additional analyses based on the sulfide and sulfone metabolites of sulindac with the same pharmacokinetic variables indicated similar chemopreventive exposures between the capsule and tablet formulations. These data support the use of sulindac capsules, which can be readily prepared with matching placebos, in future blinded chemoprevention trials. (Cancer Epidemiol Biomarkers Prev 2008;17(3):674–9)
Targeting NF-κB in Waldenstrom macroglobulinemia
Leleu, Xavier , Eeckhoute, Jérôme , Jia, Xiaoying , Roccaro, Aldo M. , Moreau, Anne-Sophie, Sacco, Antonio , Ngo, Hai T., Runnels, Judith, Melhem, Molly, Burwick, Nicolas, Azab, Abdelkareem, Azab, Feda, Hunter, Zachary R. , Hatjiharissi, Evdoxia , Carrasco, Daniel R., Hideshima, Teru , Brown, Myles , Farag, Mena S. , Treon, Steven P. , Witzig, Thomas E. , Anderson, Kenneth C. , Ghobrial, Irene M. , Roccaro, Aldo M , Hunter, Zachary R , Brown, Myles

Mayo Clinic

Blood | March 12, 2008 | Volume: 111 | Issue: 10 | Pages: 5068-5077

10.1182/blood-2007-09-115170 | PMID 18334673 Get It

Abstract The nuclear factor-κB (NF-κB) path-way has been implicated in tumor B-cell survival, growth, and resistance to therapy. Because tumor cells overcome single-agent antitumor activity, we hypothesized that combination of agents that target differentially NF-κB pathway will induce significant cytotoxicity. Therapeutic agents that target proteasome and Akt pathways should induce significant activity in B-cell malignancies as both pathways impact NF-κB activity. We demonstrated that perifosine and bortezomib both targeted NF-κB through its recruitment to the promoter of its target gene IκB using chromatin immunoprecipitation assay. This combination led to synergistic cytotoxicity in Waldenstrom macroglobulinemia (WM) cells that was mediated through a combined reduction of the PI3K/Akt and ERK signaling pathways, found to be critical for survival of WM cells. Moreover, a combination of these drugs with the CD20 monoclonal antibody rituximab further increased their cytotoxic activity. Thus, effective WM therapy may require combination regimens targeting the NF-κB pathway.
Genome Screen to Detect Linkage to Intracranial Aneurysm Susceptibility Genes
Sauerbeck, Laura, Brown, Robert D., Anderson, Craig S. , Woo, Daniel , Kleindorfer, Dawn , Flaherty, Matthew L. , Deka, Ranjan , Hornung, Richard, Meissner, Irene, Bailey‐Wilson, Joan E. , Connolly, E. Sander , Koller, Daniel L., Investigators, the FIA Study, Derdeyn, Colin P. , Hankey, Graeme J. , Ringer, Andrew J. , Tirschwell, David , Ogilvy, Christopher S. , Foroud, Tatiana , Rouleau, Guy Armand , Lai, Dongbing , Huston, John , Broderick, Joseph P. , Investigators, the FIA Study, Wilson, Richard K , Hankey, Graeme J , Ogilvy, Christopher S , Derdeyn, Colin P

Mayo Clinic

Stroke | March 7, 2008 | Volume: 39 | Issue: 5 | Pages: 1434-1440

10.1161/strokeaha.107.502930 | PMID 18323491 Get It

Background and Purpose— Evidence supports a substantial genetic contribution to the risk of intracranial aneurysm (IA). The purpose of this study was to identify chromosomal regions likely to harbor genes that contribute to the risk of IA. Methods— Multiplex families having at least 2 individuals with “definite” or “probable” IA were ascertained through an international consortium. First-degree relatives of individuals with IA who were at increased risk of an IA because of a history of hypertension or present smoking were offered cerebral magnetic resonance angiography. A genome screen was completed using the Illumina 6K SNP system, and the resulting data from 192 families, containing 1155 genotyped individuals, were analyzed. Narrow and broad disease definitions were used when testing for linkage using multipoint model-independent methods. Ordered subset analysis was performed to test for a gene×smoking (pack-years) interaction. Results— The greatest evidence of linkage was found on chromosomes 4 (LOD=2.5; 156 cM), 7 (LOD=1.7; 183 cM), 8 (LOD=1.9; 70 cM), and 12 (LOD=1.6; 102 cM) using the broad disease definition. Using the average pack-years for the affected individuals in each family, the genes on chromosomes 4 (LOD=3.5; P =0.03), 7 (LOD=4.1; P =0.01) and 12 (LOD=3.6; P =0.02) all appear to be modulated by the degree of smoking in the affected members of the family. On chromosome 8, inclusion of smoking as a covariate did not significantly strengthen the linkage evidence, suggesting no interaction between the loci in this region and smoking. Conclusions— We have detected possible evidence of linkage to 4 chromosomal regions. There is potential evidence for a gene×smoking interaction with 3 of the loci.
Plasma Free Fatty Acid Storage in Subcutaneous and Visceral Adipose Tissue in Postabsorptive Women
Koutsari, Christina , Dumesic, Daniel A. , Patterson, Bruce W. , Votruba, Susanne B. , Jensen, Michael D.

Mayo Clinic

Diabetes | February 20, 2008 | Volume: 57 | Issue: 5 | Pages: 1186-1194

10.2337/db07-0664 | PMID 18285557 Get It

OBJECTIVE— We assessed the direct (VLDL-triglycerides [VLDL-TG] independent) storage of circulating free fatty acids (FFAs) in visceral and subcutaneous fat in postabsorptive women. RESEARCH DESIGN AND METHODS— Twelve women (BMI 29.6 ± 6.6 kg/m2) received an identical, intravenous bolus dose of [1-14C]oleate followed by timed subcutaneous fat biopsies (abdominal and femoral) and then omental fat biopsy during tubal ligation surgery. Regional fat masses were assessed by combining dual-energy X-ray absorptiometry and computed tomography scanning. Separately, we assessed the fraction of FFA tracer entering VLDL-TG over the time representing the delay in collecting omental fat. RESULTS— Site-specific fat specific activity (SA) (dpm/g lipid) decreased as a function of fat mass in both upper-body subcutaneous (UBSQ) and visceral fat depots. These patterns are consistent with dilution of a relatively fixed amount of FFA tracer within progressively greater amounts of fat. Interestingly, femoral SA did not vary as a function of lower-body subcutaneous (LBSQ) fat mass. [1-14C]oleate storage per million LBSQ adipocytes was positively associated with LBSQ fat mass, but no significant relationships were observed in UBSQ or visceral fat depot. The fraction of [1-14C]oleate stored in UBSQ, LBSQ, and visceral fat was 6.7 ± 3.2, 4.9 ± 3.4, and 1.0 ± 0.3%, respectively. Only ∼4% of the tracer traversed VLDL-TG over 9.5 h. CONCLUSIONS— The increase in FFA tracer storage per adipocyte as a function of LBSQ fat mass implies that LBSQ adipocytes, in contrast to UBSQ and omental adipocytes, store more FFA in women with greater adiposity. The direct FFA storage pathway might play a role in favoring lower-body fat accumulation in women.
Surrogate endpoint validation: statistical elegance versus clinical relevance
Green, EM, Yothers, Greg , Sargent, Daniel J. , Sargent, Daniel J , Yothers, Greg

Mayo Clinic

Statistical Methods in Medical Research | February 18, 2008 | Volume: 17 | Issue: 5 | Pages: 477-486

10.1177/0962280207081863 | PMID 18285438 Get It

A variety of approaches have been proposed to provide formal and informal validation of proposed surrogate markers. To achieve true clinical impact, the validation must convince both the statistical and clinical communities. In this paper, we argue that the best approach is not a single method but a multi-faceted exploration, using multiple approaches, including those that directly appeal to clinicians but with less statistical foundation and those arising from statistical considerations but more difficult to interpret clinically. We illustrate our approach using data from clinical trials in both early and advanced colorectal cancer.
Adrenocortical carcinoma survival rates correlated to genomic copy number variants
Stephan, Elizabeth, Chung, Tae‐Hoon , Grant, Clive S., Kim, Seungchan , Hoff, Daniel D. Von , Trent, Jeffrey M. , Demeure, Michael J. , Chung, Tae-Hoon

Mayo Clinic

Molecular Cancer Therapeutics | February 15, 2008 | Volume: 7 | Issue: 2 | Pages: 425-431

10.1158/1535-7163.mct-07-0267 | PMID 18281524 Get It

Abstract Adrenocortical carcinoma (ACC) is a rare endocrine malignancy accounting for between 0.02% and 0.2% of all cancer deaths. Surgical removal offers the only current potential for cure. Unfortunately, ACC has undergone metastatic spread in 40% to 70% of patients at the time of diagnosis. Standard chemotherapy with mitotane is often ineffective with intolerable side effects. The modern molecular technology of comparative genomic hybridization allows the examination of DNA for chromosomal alterations, which can lend biological insight into cancer processes. Genomes of 25 ACC clinical samples were queried on the Agilent 44K Human Genome comparative genomic hybridization array detecting regions of chromosomal gain and loss within the tumor population. Commonly shared amplifications appearing in ≥50% of tumors at P ≤ 10−4 include regions within chromosomes 5, 7, 12, 16q, and 20. Deleted genomic regions within ACC include portions of chromosomes 1, 3p, 10q, 11, 14q, 15q, 17, and 22q. Genomic aberrations in regions associated with differential survival (P ≤ 0.05) and presence in ≥20% of tumors include amplifications of 6q, 7q, 12q, and 19p. Deletions within stratified survival groups include localized regions within 3, 8, 10p, 16q, 17q, and 19q. Statistical analysis of this genetic landscape reveals a set of chromosomal aberrations strongly associated with survival in an accumulation-dependent fashion. These regions may hold prognostic indicators and offer therapeutic targets that can be used to develop novel treatments for aggressive tumors. [Mol Cancer Ther 2008;7(2):425–31]
Clonally related follicular lymphomas and histiocytic/dendritic cell sarcomas: evidence for transdifferentiation of the follicular lymphoma clone
Martı́nez, Antonio , Burke, Jerome S., Raffeld, Mark , Camós, Mireia , Warnke, Roger A., Feldman, Andrew L. , Arber, Daniel A. , Pittaluga, Stefania , Jaffe, Elaine S.

Mayo Clinic

Blood | February 13, 2008 | Volume: 111 | Issue: 12 | Pages: 5433-5439

10.1182/blood-2007-11-124792 | PMID 18272816 Get It

Abstract Rare cases of histiocytic and dendritic cell (H/DC) neoplasms have been reported in patients with follicular lymphoma (FL), but the biologic relationship between the 2 neoplasms is unknown. We studied 8 patients with both FL and H/DC neoplasms using immunohistochemistry, fluorescence in situ hybridization (FISH) for t(14;18), and polymerase chain reaction (PCR)/sequencing of BCL2 and IGH rearrangements. There were 5 men and 3 women (median age, 59 years). All cases of FL were positive for t(14;18). The H/DC tumors included 7 histiocytic sarcomas, 5 of which showed evidence of dendritic differentiation, and 1 interdigitating cell sarcoma. Five H/DC tumors were metachronous, following FL by 2 months to 12 years; tumors were synchronous in 3. All 8 H/DC tumors showed presence of the t(14;18) either by FISH, or in 2 cases by PCR with the major breakpoint region (MBR) probe. PCR and sequencing identified identical IGH gene rearrangements or BCL2 gene breakpoints in all patients tested. All H/DC tumors lacked PAX5, and up-regulation of CEBPβ and PU.1 was seen in all cases tested. These results provide evidence for a common clonal origin of FL and H/DC neoplasms when occurring in the same patient, and suggest that lineage plasticity may occur in mature lymphoid neoplasms.
Altered neuronal gene expression in brain regions differentially affected by Alzheimer's disease: a reference data set
Liang, Winnie S. , Dunckley, Travis , Beach, Thomas G. , Grover, Andrew, Mastroeni, Diego , Ramsey, Keri , Caselli, Richard J. , Kukull, Walter A. , McKeel, Daniel W., Morris, John C. , Hulette, Christine M., Schmechel, Donald E., Reiman, Eric M. , Rogers, Joseph, Stephan, Dietrich A. , Morris, John C

Mayo Clinic

Physiological Genomics | February 12, 2008 | Volume: 33 | Issue: 2 | Pages: 240-256

10.1152/physiolgenomics.00242.2007 | PMID 18270320 Get It

Alzheimer's Disease (AD) is the most widespread form of dementia during the later stages of life. If improved therapeutics are not developed, the prevalence of AD will drastically increase in the coming years as the world's population ages. By identifying differences in neuronal gene expression profiles between healthy elderly persons and individuals diagnosed with AD, we may be able to better understand the molecular mechanisms that drive AD pathogenesis, including the formation of amyloid plaques and neurofibrillary tangles. In this study, we expression profiled histopathologically normal cortical neurons collected with laser capture microdissection (LCM) from six anatomically and functionally discrete postmortem brain regions in 34 AD-afflicted individuals, using Affymetrix Human Genome U133 Plus 2.0 microarrays. These regions include the entorhinal cortex, hippocampus, middle temporal gyrus, posterior cingulate cortex, superior frontal gyrus, and primary visual cortex. This study is predicated on previous parallel research on the postmortem brains of the same six regions in 14 healthy elderly individuals, for which LCM neurons were similarly processed for expression analysis. We identified significant regional differential expression in AD brains compared with control brains including expression changes of genes previously implicated in AD pathogenesis, particularly with regard to tangle and plaque formation. Pinpointing the expression of factors that may play a role in AD pathogenesis provides a foundation for future identification of new targets for improved AD therapeutics. We provide this carefully phenotyped, laser capture microdissected intraindividual brain region expression data set to the community as a public resource.